Skip to main content

Table 3 Main medical treatment of CD and UC

From: Study of disease phenotype and its association with prognosis of paediatric inflammatory bowel disease in China

Treatment

Number of patients (%)

CD (n = 113)

UC (n = 30)

IBD (n = 143)

Induction therapy

 Corticosteroids

57 (50.4)

18 (60.0)

75 (52.4)

 Mesalazine

29 (25.7)

25 (83.3)

54 (37.8)

 Biological agent

65 (45.5)

5 (16.7)

70 (49.0)

 Thalidomide

14 (12.4)

3 (10.0)

17 (11.9)

Maintenance therapya

 Azathioprine

54 (47.8)

6 (20.0)

60 (42.0)

 Biological agent

48 (42.5)

2 (6.7)

50 (35.0)

 Thalidomide

32 (28.3)

3 (10.0)

35 (24.5)

 Mesalazine

23 (20.4)

21 (70.0)

44 (30.8)

 Methotrexate

3 (2.7)

0

3 (2.1)

 Cyclosporine A

2 (1.8)

0 (0.0)

2 (1.4)

 Total enteral nutrition

2 (1.8)

0 (0.0)

2 (1.4)

 Corticosteroids

31 (27.4)

11 (36.7)

42 (29.4)

  1. aThe data are from an analysis of the first year of maintenance therapy